We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Progenra Receives Approval of Novel Patent for Isopeptidase High Throughput Screening Platform

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Progenra Receives Approval of Novel Patent for Isopeptidase High Throughput Screening Platform"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Progenra, Inc., announced their receipt of an Official Notice of Allowance, dated June 15, 2010, of U.S. Patent Application No. 11/156,707, “Diagnostic and Screening Methods and Kits Associated with Proteolytic Activity.”

IP protection of this technology was also recently granted by the European Union. This technology is expected enable faster drug discovery by improving the ability to identify more selective drugs that modulate the handling of proteins associated with various disease states.

“This is a huge step forward, not only for Progenra, but for the industry,” said Michael Mattern, COO of Progenra. “This process condenses the timeline for drug discovery and in understanding drug efficacy and compatibility with the human body, while avoiding unnecessary expenditures associated with R&D.”